Mogamulizumab - Kyowa Hakko Kirin

Drug Profile

Mogamulizumab - Kyowa Hakko Kirin

Alternative Names: AMG-761; KW-0761; Poteligeo

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kyowa Hakko Kirin
  • Class Antiasthmatics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Phase III Spinal cord disorders
  • Phase I/II Solid tumours
  • Research Mycosis fungoides; Sezary syndrome
  • No development reported Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 11 Dec 2017 Adverse events and efficacy data from the phase III MAVORIC trial in Cutaneous T-cell lymphoma presented at the Annual Meeting of American Society of Hematology (ASH-2017) (9228880; 9228841)
  • 30 Nov 2017 Kyowa Hakko Kirin files supplemental application to remove pre-treatment diagnostic requirement and to change dosing schedule of mogamulizumab for cutaneous T-cell lymphoma (Second-line therapy or greater) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top